New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:31 EDTXNPTXenoPort to mail letter to shareholders
XenoPort announced that it is mailing a letter to stockholders in connection with the company’s upcoming Annual Meeting, which will be held on June 11. In the letter, XenoPort urges stockholders to protect the value of their investment by voting “FOR ALL” of XenoPort’s nominees to the Board of Directors on the WHITE proxy card. Highlights of the letter include: XenoPort is advancing XP23829; XenoPort is building value in HORIZANT; XenoPort’s Board is committed to fully realizing the value of XenoPort’s assets – for the benefit of all XenoPort stockholders; Clinton is waging a misleading proxy campaign to replace three of XenoPort’s proven, highly-qualified directors with three of its own handpicked nominees; and XenoPort believes Clinton’s uninformed agenda would fail to maximize the value of XenoPort’s assets. XenoPort believes Clinton’s agenda is short-term focused and puts at risk the opportunity for long-term value creation
News For XNPT From The Last 14 Days
Check below for free stories on XNPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
08:40 EDTXNPTXenoPort, NIAAA to conduct clincial trial of Horizant ER tablets
XenoPort and the National Institute on Alcohol Abuse and Alcoholism have entered into an agreement to conduct a clinical trial of HORIZANT Extended-Release Tablets as a potential treatment for alcohol use disorder. Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT. The study is planned to be a randomized, double-blind, placebo-controlled clinical trial of the safety and efficacy of HORIZANT in patients who have AUD but are abstinent at treatment initiation. The study is expected to have a treatment period of six months and to enroll approximately 350 patients beginning in the first half of 2015. XenoPort and the NIAAA are planning to meet with the U.S. Food and Drug Administration Division of Anesthesia, Analgesia and Addiction Products in the fourth quarter of 2014 to discuss the trial design and the possibility of utilizing the results of this trial as the basis for a potential supplemental new drug application submission for HORIZANT for the maintenance of abstinence from heavy drinking of alcohol in patients with AUD.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use